Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 60.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,306 shares of the specialty pharmaceutical company’s stock after acquiring an additional 25,004 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Supernus Pharmaceuticals were worth $2,398,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Barclays PLC grew its holdings in Supernus Pharmaceuticals by 88.3% in the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after purchasing an additional 51,005 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter worth about $791,000. Geode Capital Management LLC grew its stake in Supernus Pharmaceuticals by 5.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after acquiring an additional 74,438 shares during the last quarter. Franklin Resources Inc. increased its holdings in Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after acquiring an additional 2,121 shares in the last quarter. Finally, Bank of Montreal Can raised its position in Supernus Pharmaceuticals by 1,508.0% during the second quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock worth $3,287,000 after acquiring an additional 109,088 shares during the last quarter.

Insiders Place Their Bets

In related news, CEO Jack A. Khattar sold 125,000 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the transaction, the chief executive officer now owns 926,172 shares of the company’s stock, valued at approximately $33,971,988.96. This represents a 11.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the sale, the senior vice president now directly owns 8,200 shares of the company’s stock, valued at $303,236. This represents a 64.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 154,213 shares of company stock valued at $5,660,180. Insiders own 9.30% of the company’s stock.

Analyst Upgrades and Downgrades

SUPN has been the subject of a number of recent research reports. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cantor Fitzgerald began coverage on Supernus Pharmaceuticals in a research report on Monday, January 6th. They set an “overweight” rating and a $57.00 price target for the company. Finally, Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN opened at $37.74 on Friday. The firm has a market cap of $2.08 billion, a PE ratio of 35.27 and a beta of 0.90. The firm has a 50 day simple moving average of $36.67 and a 200-day simple moving average of $33.65. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.25. The company had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. Supernus Pharmaceuticals’s revenue was up 14.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.29) EPS. As a group, sell-side analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.